Halozyme lands $20M loan; BrainStorm touts a patient's apparent response to adult stem cell therapy;

@FierceBiotech: FierceBiotech's first special report of 2014: An ominous trend resurfaces as new drug approvals plunge in 2013. Report | Follow @FierceBiotech

@JohnCFierce: GE beefs up life sciences division with $1.06B Thermo Fisher deal. Story | Follow @JohnCFierce

@DamianFierce: "Moon Shots" = excellent naming. MD Anderson teams up with Pfizer to advance cancer immunotherapy. Release | Follow @DamianFierce

@EmilyMFierce: 6 U.S. institutions receive $540M in cancer research funds. Item | Follow @EmilyMFierce

> San Diego-based Halozyme Therapeutics ($HALO) has obtained a $20 million loan from Oxford Finance and Silicon Valley Bank. Release

> Israel's BrainStorm Cell Therapeutics is touting the response of a single elderly patient with Lou Gehrig's disease and myasthenia gravis to a therapy using its adult stem cells. Story

Medical Device News

@FierceMedDev: TrovaGene recruits US Oncology Research for a pancreatic cancer Dx trial. News | Follow @FierceMedDev

@MichaelGFierce: Gene delivery method 'hijacks' tumor blood vessels. More | Follow @MichaelGFierce

> Medtronic gives it another go with atrial fibrillation device. News

> Topera snags FDA OK for latest heart-mapping tech. Story

> Quest beefs up its Indian presence as stateside sales sag. Piece

> Thermo nears Life Tech merger with $1.1B sale to GE. Article

Pharma News

@FiercePharma: Rebel Teva shareholder throws his support to presumptive CEO Vigodman. Story | Follow @FiercePharma

@EricPFierce: There were fewer NDA's approved by the FDA in 2013, but there were some significant ones. Report | Follow @EricPFierce

@CarlyHFierce: Bayer's hot-selling Eylea runs into a roadblock in its home market. More | Follow @CarlyHFierce

> Rebel Teva shareholder throws his support to presumptive CEO Vigodman. News

> Celgene, Boston Children's play tug-of-war over Revlimid royalties. Article

> Is the audience listening? FDA wants to spy on social media to find out. More

CRO News

> Cyprotex bags a U.S. CRO for up to $5.1M. Report

> DaVita ups its CRO weight with latest partnership. News

> Sanofi stops short of baring it all with clinical trial transparency pledge. More

> Can Parexel regain some confidence after a major slip? Article

> India further tightens clinical trial rules as demand plummets. Story

> Report: Big or small, CROs need good relationships to thrive. Item

Biotech IT News

> Google VC commits to $15M round to advance DNAnexus' data hub ambitions. Report

> NIH puts improved data handling at top of BRAIN Initiative wish list. Story

> FDA plans raft of IT guidance documents to further GDUFA goals. News

> Days after Big Pharma trumpets data sharing plans, U.K. politicians push for more transparency. Article

> Spun out of George Church's lab, Curoverse gets $1.5M for open-source bio Big Data. More

> IMS Health files for IPO after making string of tech takeovers. Item

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.